Featuring perspectives from Drs Tanios Bekaii-Saab, Scott Kopetz, and John Strickler and Prof Eric Van Cutsem, moderated by Dr Kristen Ciombor, including the following topics:
• Integration of Therapies Targeting BRAF and HER2 in Metastatic Colorectal Cancer (mCRC) — Dr Strickler
o Introduction (0:00)
o Case: A man in his early 40s presenting with microsatellite-stable (MSS) rectal cancer and liver metastases — Victoria Giffi, MD (2:04)
o Cases: A man in his late 70s with HER2-amplified colon cancer and extensive liver metastases and a man in his late 50s with KRAS G12S-mutant HER2-amplified colon cancer and lung metastases — Ranju Gupta, MD and Shaachi Gupta, MD, MPH (9:12)
o Faculty presentation (16:39)
• Optimizing the Use of Immune Checkpoint Inhibitors in the Management of mCRC — Dr Ciombor
o Case: A man in his mid 50s with BRAF V600E-mutant, KRAS/NRAS wild-type metastatic colon cancer with disease progression on FOLFOXIRI/bevacizumab — Lai (Amber) Xu, MD, PhD (26:13)
o Case: A man in his late 60s with localized unresectable microsatellite instability-high carcinoma of the cecum — Farshid Dayyani, MD, PhD (32:02)
o Faculty presentation (41:11)
• Evidence-Based Selection and Sequencing of Therapy for Patients with mCRC — Prof Van Cutsem
o Case: A man in his late 70s with metastatic rectal cancer and newly diagnosed PMS2-positive Lynch syndrome — Liudmila N Schafer, MD (51:39)
o Case: A man in his mid 50s with pan-RAS wild-type metastatic rectal cancer treated with FOLFOX/cetuximab — Warren S Brenner, MD (56:55)
o Faculty presentation (1:03:36)
• Promising Agents and Strategies for Patients with mCRC — Dr Bekaii-Saab
o Case: A woman in her early 50s with KRAS and BRAF wild-type, HER2-negative T3N1 rectal cancer with liver and lung oligometastases who underwent multiple ablations and stereotactic body radiation therapy and is currently receiving FOLFIRI/panitumumab – MSS, mismatch repair-proficient, PD-L1 0% — Jennifer L Dallas, MD (1:13:13)
o Case: A woman in her early 60s with metastatic KRAS G12C-mutant cancer of the sigmoid colon — Philip L Brooks, MD (1:18:43)
o Faculty presentation (1:22:32)
• The Changing Management Paradigm for Localized CRC — Dr Kopetz
o Case: A man in his early 70s with 2 synchronous T3N0 cancers of the splenic flexure and cecum who is found to have circulating tumor DNA after resection — Dr Brenner (1:35:56)
o Case: A man in his early 80s with a Stage II obstructing cancer of the right colon — Namrata I Peswani, MD (1:46:12)
o Faculty presentation (1:47:58)
CME information and select publications
Our TOPPODCAST Picks 
Stay Connected
